In the claims:

1. (Currently Amended) A compound of Formula I



I

wherein

R^1 is selected from

~~1)~~ hydrogen,

~~2)~~ halogen,

~~3)~~ substituted or unsubstituted C_1-C_{10} alkyl,

~~4)~~ substituted or unsubstituted C_2-C_{10} alkenyl,

~~5)~~ substituted or unsubstituted C_2-C_{10} alkynyl,

~~6)~~ substituted or unsubsituted aryl,

~~7)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl,

~~8) substituted or unsubstituted heterocyclyl,~~

~~9)~~ $-(CR^a_2)_nOR^4$, and

~~10)~~ $-(CR^a_2)_tC(O)OR^4$;

said alkyl, alkenyl, alkynyl, aryl, and cycloalkyl~~, and heterocyclyl~~ is optionally substituted with one or more of R^7;

R^2 is selected from

~~1)~~ hydrogen,

~~2)~~ substituted or unsubstituted aralkyl,

~~3)~~ substituted or unsubstituted C_1-C_{10} alkyl,

~~4) substituted or unsubstituted heterocyclyl,~~

~~5)~~ substituted or unsubstituted aryl, and

~~6)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl;

R^3 is selected from

~~1)~~ hydrogen,
~~2)~~ halogen,
~~3)~~ $-C(O)R^4$,
~~4)~~ substituted or unsubstituted C_1-C_{10} alkyl,
~~5)~~ substituted or unsubstituted aryl,
~~6) substituted or unsubstituted heterocyclyl,~~
~~7)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl,
~~8)~~ substituted or unsubstituted C_2-C_{10} alkenyl, and
~~9)~~ substituted or unsubstituted C_2-C_{10} alkynyl;

R^4 is independently selected from

~~1)~~ hydrogen,
~~2)~~ substituted or unsubstituted C_1-C_{10} alkyl,
~~3)~~ substituted or unsubstituted aryl,
~~4) substituted or unsubstituted heterocyclyl,~~
~~5)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl,
~~6)~~ substituted or unsubstituted C_2-C_{10} alkenyl, and
~~7)~~ substituted or unsubstituted C_2-C_{10} alkynyl;

R^6 is independently selected from

~~1)~~ substituted or unsubstituted aryl,
~~2) substituted or unsubstituted heterocyclyl,~~
~~3)~~ substituted or unsubstituted cycloalkyl, and
~~4)~~ halogen;

R^7 is independently selected from

~~1)~~ hydrogen,
~~2)~~ halogen,
~~3)~~ substituted or unsubstituted C_1-C_{10} alkyl,
~~4)~~ substituted or unsubstituted C_2-C_{10} alkenyl,
~~5)~~ substituted or unsubstituted C_2-C_{10} alkynyl,

~~6)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl,

~~7)~~ substituted or unsubstituted aryl,

~~8) substituted or unsubstituted heterocyclyl,~~

~~9)~~ $-NO_2$,

~~10)~~ $-NR^4(CR^a_2)_nC(O)R^4$,

~~11)~~ $-(CR^a_2)_nNR^4_2$,

~~12)~~ $-(CR^a_2)_nNR^4(CR^a_2)_nR^6$,

~~13)~~ –CN,

~~14)~~ $-(CR^a_2)_nC(O)R^4$,

~~15)~~ $-(CR^a_2)_nC(O)(CR^a_2)_nOR^4$,

~~16)~~ $-(CR^a_2)_nOR^4$,

~~17)~~ $-(CR^a_2)_nR^6$,

~~18)~~ $-(CR^a_2)_nC(O)OR^4$, and

~~19)~~ $-(CR^a_2)_nSi(R^4)_3$;

R^a is independently selected from

~~1)~~ hydrogen,

~~2)~~ substituted or unsubstituted C_1-C_{10} alkyl,

~~3)~~ substituted or unsubstituted C_2-C_{10} alkenyl,

~~4)~~ substituted or unsubstitute C_2-C_{10} alkynyl,

~~5)~~ $-OR^4$,

~~6)~~ $-C(O)OR^4$,

~~7)~~ $-NR^4_2$,

~~8)~~ substituted or unsubstituted aryl,

~~9) substituted or unsubstituted heterocyclyl,~~ and

~~10)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl;

n is independently 0 to 6;

t is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. (Currently Amended) The compound according to Claim 1, wherein

R^1 is selected from

1) hydrogen,
2) halogen,
3) substituted or unsubstituted C_1-C_6 alkyl,
4) substituted or unsubstituted C_2-C_{10} alkynyl,
5) substituted or unsubsituted aryl, and
6) substituted or unsubstituted C_3-C_{10} cycloalkyl, ~~and~~
~~7) substituted or unsubstituted heterocyclyl;~~

said alkyl, alkynyl, aryl, and cycloalkyl~~, and heterocyclyl~~ is optionally substituted with one or more of R^7;

R^2 is selected from

1) substituted or unsubstituted aralkyl,
2) substituted or unsubstituted C_1-C_6 alkyl,
3) substituted or unsubstituted aryl, and
4) substituted or unsubstituted C_3-C_{10} cycloalkyl;

R^3 is selected from

1) halogen,
2) $-C(O)R^4$, and
3) substituted or unsubstituted C_1-C_6 alkyl;

R^4 is independently selected from

~~1)~~ hydrogen,
~~2)~~ substituted or unsubstituted C_1-C_6 alkyl,
~~1)~~ substituted or unsubstituted aryl, and
~~2) substituted or unsubstituted heterocyclyl, and~~
~~3)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. (Currently Amended) The compound according to Claim 2,

wherein

R^1 is selected from

~~1)~~ substituted or unsubstituted C_1-C_6 alkyl,

~~2)~~ substituted or unsubstituted C_2-C_{10} alkynyl, and

~~3) substituted or unsubstituted heterocyclyl and~~

~~4)~~ substituted or unsubstituted aryl;

said alkyl, alkynyl, ~~heterocyclyl~~ and aryl is optionally substituted with one or more of R^7;

R^2 is selected from

1) substituted or unsubstituted aralkyl, and
2) substituted or unsubstituted C_1-C_6 alkyl;

R^3 is selected from

1) halogen, and
2) $-C(O)R^4$;

or a pharmaceutically acceptable salt or stereoisomer thereof.

4. (Currently Amended) A compound of Formula II



II

wherein

R^1 is selected from

1) hydrogen,
2) halogen,
3) substituted or unsubstituted C_1-C_6 alkyl,
4) substituted or unsubstituted C_2-C_{10} alkynyl,

5) substituted or unsubstituted aryl, and
6) substituted or unsubstituted C_3-C_{10} cycloalkyl, ~~and~~
~~7) substituted or unsubstituted heterocyclyl;~~

said alkyl, alkynyl, aryl, and cycloalkyl ~~and heterocyclyl~~ is optionally substituted with one or more of R^7;

R^2 is selected from

1) substituted or unsubstituted aralkyl, and
2) substituted or unsubstituted C_1-C_6 alkyl;

R^4 is independently selected from

~~1)~~ hydrogen,
~~2)~~ substituted or unsubstituted C_1-C_{10} alkyl,
~~3)~~ substituted or unsubstituted aryl,
~~4) substituted or unsubstituted heterocyclyl,~~
~~5)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl,
~~6)~~ substituted or unsubstituted C_2-C_{10} alkenyl, and
~~7)~~ substituted or unsubstituted C_2-C_{10} alkynyl;

R^6 is independently selected from

~~1)~~ substituted or ~~unsubsituted~~ unsubstituted aryl,
~~2) substituted or unsubstituted heterocyclyl,~~
~~3)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl, and
~~4)~~ halogen;

R^7 is independently selected from

~~1)~~ hydrogen,
~~2)~~ halogen,
~~3)~~ substituted or unsubstituted C_1-C_{10} alkyl,
~~4)~~ substituted or unsubstituted C_2-C_{10} alkenyl,
~~5)~~ substituted or unsubstituted C_2-C_{10} alkynyl,
~~6)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl,
~~7)~~ substituted or unsubstituted aryl,
~~8) substituted or unsubstituted heterocyclyl,~~

~~9)~~ $-NO_2$,
~~10)~~ $-NR^4(CR^a_2)_nC(O)R^4$,
~~11)~~ $-(CR^a_2)_nNR^4_2$,
~~12)~~ $-(CR^a_2)_nNR^4(CR^a_2)_nR^6$,
~~13)~~ –CN,
~~14)~~ $-(CR^a_2)_nC(O)R^4$,
~~15)~~ $-(CR^a_2)_nC(O)(CR^a_2)_nOR^4$,
~~16)~~ $-(CR^a_2)_nOR^4$,
~~17)~~ $-(CR^a_2)_nR^6$,
~~18)~~ $-(CR^a_2)_nC(O)OR^4$, and
~~19)~~ $-(CR^a_2)_nSi(R^4)_3$;

R^a is independently selected from

~~1)~~ hydrogen,
~~2)~~ substituted or unsubstituted C_1-C_{10} alkyl,
~~3)~~ substituted or unsubstituted C_1-C_{10} alkenyl,
~~4)~~ substituted or unsubstitute C_1-C_{10} alkynyl,
~~5)~~ $-OR^4$,
~~6)~~ $-C(O)OR^4$,
~~7)~~ $-NR^4_2$,
~~8)~~ substituted or unsubstituted aryl, and
~~9) substituted or unsubstituted heterocyclyl, and~~
~~10)~~ substituted or unsubstituted C_3-C_{10} cycloalkyl;

n is independently 0 to 6;
t is 1 to 4;

or a pharmaceutically acceptable salt or stereoisomer thereof.

5. (Currently Amended) A compound selected from:

benzyl 4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2,5-diiodo-1H-pyrrole-3-carboxylate;

methyl 5-(4-fluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-thien-2-yl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[3-(trimethylsilyl)prop-1-ynyl]-1H-pyrrole-3-carboxylate;

4'-benzyl 1-tert-butyl 3'-ethyl-5'-formyl-1H,1'H-2,2'-bipyrrole-1,4'-dicarboxylate;

benzyl 5-(3,5-dimethylisoxazol-4-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(1-benzofuran-2-yl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-nitrophenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(5-methyl-2-furyl)-1H-pyrrole-3-carboxylate;

benzyl 5-[3-(acetylamino)phenyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate;

benzyl 5-(3-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-methoxyphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(5-formyl-2-furyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(phenylethynyl)-1H-pyrrole-3-carboxylate;

methyl 5-{3-[benzyl(methyl)amino]prop-1-ynyl}-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(2-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(4-cyanophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(4-methoxyphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(2-methylphenyl)-1H-pyrrole-3-carboxylate;

benzyl 4-ethyl-2-formyl-5-(3-methylphenyl)-1H-pyrrole-3-carboxylate;

benzyl 5-(2-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

benzyl 5-(3-chlorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[1-(3-hydroxypropyl)vinyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(5-hydroxypent-1-ynyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate;

methyl 5-[3-(dimethylamino)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(3,3-dimethylbut-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(pyridin-2-ylethynyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methoxyprop-1-ynyl)-1H-pyrrole-3-carboxylate;

methyl 5-[(2-bromophenyl)ethynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;
methyl 5-[3-(1H-1,2,3-benzotriazol-1-yl)prop-1-ynyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-5-(2-ethylbutyl)-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 5-(4-tert-butylphenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(2,4-difluorophenyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[3-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[4-(methoxycarbonyl)phenyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclopentyl)ethynyl]-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-methylbut-1-ynyl)-1H-pyrrole-3-carboxylate

methyl 4-ethyl-2-formyl-5-(1-hexylvinyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(1,3-thiazol-2-yl)-1H-pyrrole-3-carboxylate;

methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(5-chloropent-1-ynyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-hydroxy-3-phenylbut-1-ynyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-isopentyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methylthien-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-isobutyl-1H-pyrrole-3-carboxylate;

methyl 5-cyclohexyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-cyclopentyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-(cyclohexylmethyl)-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 5-sec-butyl-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(3-methoxy-2-methyl-3-oxopropyl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-nitrophenyl)-1H-pyrrole-3-carboxylate; and

methyl 4-ethyl-2-formyl-5-(2-methoxyphenyl)-1H-pyrrole-3-carboxylate;

or a pharmaceutically acceptable salt or stereoisomer thereof.

6. (Currently Amended) The compound according Claim 5 that is selected from

methyl 4-ethyl-2-formyl-5-iodo-1H-pyrrole-3-carboxylate



;

benzyl 4-ethyl-2-formyl-5-phenyl-1H-pyrrole-3-carboxylate



;

methyl 4-ethyl-2-formyl-5-[(1-hydroxycyclohexyl)ethynyl]-1H-pyrrole-3-carboxylate



;

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate



; and

methyl 5-[1-(3-chloropropyl)vinyl]-4-ethyl-2-formyl-1H-pyrrole-3-carboxylate



;

or a pharmaceutically acceptable salt or stereoisomer thereof.

7. (Currently Amended) A trifluoroacetic acid salt of a compound of Claim 5 which is selected from

methyl 4-ethyl-2-formyl-5-(6-methoxypyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(4-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate;

methyl 4-ethyl-2-formyl-5-(6-methylpyridin-2-yl)-1H-pyrrole-3-carboxylate; and

benzyl 4-ethyl-2-formyl-5-pyridin-4-yl-1H-pyrrole-3-carboxylate.

8. (Original) A pharmaceutical composition which is comprised of a compound in accordance with Claim 1 and a pharmaceutically acceptable carrier.

9. (Original) A method of modulating the catalytic activity of protein kinases in a mammal in need thereof comprising contacting the protein kinase with a compound of Claim 1.

10. (Original) The method of Claim 9 wherein the protein kinase is an RTK.

11. (Original) The method of Claim 10, wherein the RTK is selected from IR, IGF-1R and IRR.

12. (Original) A method of treating a PK-related disorder in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

13. (Currently Amended) ~~A~~ The method of Claim 12, wherein the PK-related disorder is an IGF-1R-related disorder selected from:

1) cancer,
2) diabetes,
3) an autoimmune disorder,
4) a hyperproliferation disorder,
5) aging,
6) acromegaly, and
7) Crohn's disease.

14. (Cancelled)

15. (Cancelled)

16. (Original) A method of treating cancer in a mammal in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of Claim 1.

17. (Original) A method of treating retinal vascularization comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

18. (Cancelled)

19. (Cancelled)

20. (Cancelled)

21. (Cancelled)

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)

26. (Cancelled)

27. (Cancelled)

28. (Cancelled)

29. (Cancelled)

30. (Cancelled)